Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi India's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was ₹1,126 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹4,371 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Sanofi India's annualizedROC % for the quarter that ended in Jun. 2026 was 48.66%.
Sanofi India's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 134.97%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Sanofi India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 5.95%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi India EBIT Related Terms
Sanofi India EBIT Historical Data
* Premium members only.
The historical data trend for Sanofi India's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sanofi India's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,371 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi India (NSE:SANOFI) has a EBIT of ₹4,371 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanofi India.
Is Sanofi India's EBIT too high?
Sanofi India's current EBIT is ₹4,371 Mil. Overall, Sanofi India has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's EBIT compare to LLY and JNJ?
Sanofi India's EBIT of ₹4,371 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sanofi India. Sanofi India's current EBIT is ₹4,371 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (NSE:SANOFI) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,397.51, compared to a current price of ₹3,352.80 — trading 23.8% below its estimated fair value. The current EBIT is ₹4,371 Mil. Sanofi India's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sanofi India (NSE:SANOFI), the current EBIT is ₹4,371 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (NSE:SANOFI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,352.80 is trading 23.8% below its estimated GF Value™ of ₹4,397.51.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for NSE:SANOFI:
EBIT: ₹4,371 Mil
GF Value™: ₹4,397.51 vs. price of ₹3,352.80 (23.8% below fair value)
No single metric tells the full story. See the NSE:SANOFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
82GF Score
Get the complete analysis for NSE:SANOFI
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFI has been successfully added to your 
